PANTOPRAZOLE 40mg. IP + CINITAPRIDE 3mg. IP

A dual-mechanism therapy used for acid-related and motility-related gastrointestinal disorders. The combination of Cinitapride and Pantoprazole is commonly prescribed for patients with non-ulcer dyspepsia and gastroesophageal reflux disease (GERD). (G.H. Patel, 2011) Provides sustained gastric acid suppression and promotes mucosal healing. Reduces stomach acid production by inhibiting the proton pump (H⁺/K⁺-ATPase). Enhances gastrointestinal motility by increasing acetylcholine release in the gut and strengthens the lower esophageal sphincter. Produces significant reductions in key symptoms (postprandial fullness, early satiation, bloating). Accelerates gastric emptying, lowering gastric distension and pressure. Effectively and safely manages functional dyspepsia and related overlapping gastroesophageal reflux disease, irritable bowel syndrome, and functional constipation. (Bing Yan, 2025) A trusted treatment choice for acid-mediated gastrointestinal disorders. (Susan M Cheer, 2003) Provides better symptom relief by controlling acidity, reducing reflux, and improving digestive function. Effective in treating ulcers of the stomach and duodenum and in controlling Zollinger–Ellison syndrome. (G.H. Patel, 2011)